Haloperodol Injectable

Generic Name: Haloperidol

Brand Names:

Availability: Available with Prescription

Drug Class: Antipsychotics

Therapeutic action

  • Antipsychotic

Indications

  • Acute confusional state (delirium) and acute alcohol intoxication
  • Agitation or aggressive behaviour in patients with acute or chronic psychosis, in combination with promethazine

Forms and strengths, route of administration

  • 5 mg in 1 ml ampoule(5 mg/ml) for IM injection

Dosage and duration

Acute confusional state (delirium) and acute alcohol intoxication

  • Adult: 0.5 to 1 mg, to be repeated after 30 to 60 minutes if necessary. If needed, administer additional doses every 4 hours (max. 5 mg) for 7 days max.

Agitation or aggressive behaviour in patients with acute or chronic psychosis, with promethazine

  • Adult: 5 mg, to be repeated after 30 minutes if necessary

Change to oral treatment as soon as possible.

Reduce the dose by half in older patients(max. 5 mg daily).

Contra-indications, adverse effects, precautions

  • Do not administer to patients with cardiac disorders (cardiac failure, recent myocardial infarction, conduction disorders, bradycardia, etc.), dementia (e.g. Alzheimer's disease), Parkinson's disease and history of neuroleptic malignant syndrome. 
  • Administer with caution and carefully monitor use in older patients and patients with hypokalaemia, hypotension, hyperthyroidism, renal or hepatic impairment, history of seizures.
  • May cause: drowsiness, extrapyramidal syndrome, dyskinesia, anticholinergic effects (constipation, dry mouth), sexual dysfunction, QT-prolongation, ventricular arrhythmia, orthostatic hypotension; neuroleptic malignant syndrome(unexplained hyperthermia with neuromuscular disorders), rare but requiringimmediate treatment discontinuation.
  • Avoid or monitor combination with:
    • central nervous system depressants (opioid analgesics, sedatives, H1 antihistamines, etc.); 
    • fluoxetine, paroxetine, sertraline, ritonavir (increased plasma concentrations of haloperidol); 
    • carbamazepine, rifampicin, phenobarbital, phenytoin(decreased plasma concentrations of haloperidol);
    • antihypertensive drugs (risk of hypotension); drugs that prolong the QT interval (amiodarone, chloroquine, erythromycin, fluconazole, mefloquine, pentamidine, quinine, etc.).
  • Keep the patient in the supine position for 30 minutes after injection (risk of orthostatic hypotension):
  • Pregnancy: re-evaluate whether the treatment is still necessary; if it is continued, administer at the
  • lowest effective dose. Observe the neonate the first few days (risk of agitation, tremors, hypertonia/hypotonia, respiratory difficulties, sleeping disorders, etc.) if the mother was under treatment in the 3rdtrimester.
  • Breast-feeding: if absolutely necessary,do not exceed 10 mg daily.

Remarks

  • Haloperidol decanoate is a long-acting form used as maintenance therapy of chronic psychotic disorders after stablisation with oral treatment.

Storage

– Below 25 °C